Acadia stock rallies on drug news as Roivant also climbs, while Leslie’s, Theseus shares plunge and more moving stocks
Here are some of the biggest movers ahead of Friday’s market open:
Acadia Pharmaceuticals Inc.’s stock
surged 18% in premarket trading after the company expanded drug rights to a treatment for a rare neurological disorder.
Shares of Roivant Sciences Ltd.
rallied nearly 10% following a Wall Street Journal report the biotech drug maker was close to the sale of an ulcerative colitis drug to Roche Holding
JPMorgan Chase & Co. shares
rose 0.6% in premarket trading ahead of the Wall Street bank’s second-quarter results due Friday.
Theseus Pharmaceuticals Inc. shares
plummeted 64% as the drug maker announced it halted development of a cancer drug candidate.
Shares of Leslie’s Inc. fell 24% after the spa and pool supplies retailer announced preliminary quarterly results below expectations, dialed down its 2023 outlook, and announced a CFO transition.
Shares of Nokia Oyj
dropped nearly 10% in premarket trading after the Finnish telecom equipment maker lowered its full-year outlook after preliminary second-quarter results. Shares of its Swedish rival Ericsson AB
fell 8.5% after meeting expectations with its results, but giving lackluster guidance.
Shares of Caribou Biosciences Inc.
were down 4% after the biopharma company said it had begun a $100 million share offering.